Graft-vs.-malignancy with allogeneic blood stem cell transplantation: A potential primary treatment modality

Pediatric Transplantation

Volumn 3, Issue SUPPL. 1, 1999, Pages 52-58

  Champlin, R ^a   Khouri, I ^a   Giralt, S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE;

ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CONFERENCE PAPER; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; REMISSION;

EID: 0032696854     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.1999.00054.x     Document Type: Conference Paper

References (97)

1. 1 Thomas ED. Bone marrow transplantation for malignant disease. J Clin Oncol 1983: 1: 517.
2. 2 Thomas ED. The role of bone marrow transplantation for eradication of malignant disease. Cancer 1963: 10: 1969.
3. 3 Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft‐versus‐host disease in human recipients of allogeneic marrow grafts. NEJM 1979: 300: 1068.
4. 4 Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED and the Seattle Marrow Transplant Team. Antileukemic effect of chronic graft‐versus‐host disease: contribution to improved survival after allogeneic marrow transplantation. NEJM 1981: 304: 1529.
5. 5 Horowitz MM, Gale RP, Sondel PM, et al. Graft‐versus‐leukemia reactions after bone marrow transplantation. Blood 1990: 75: 555.
6. 6 Sullivan KM, Storb R, Buckner CD, et al. Graft‐versus‐host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989: 320: 828.
7. 7 Gale RP & Champlin RE. How does bone marrow transplantation cure leukemia? Lancet 1984: 2: 28.
8. 8 Gale RP, Horowitz MM, Ash RC, et al. Identical‐twin bone marrow transplants for leukemia. Ann Intern Med 1994: 120: 646.
9. 9 Fefer A, Cheever MA, Greeberg PD. Identical‐twin (Syngeneic) marrow transplantation for hematologic cancers. J Natl Cancer Inst 1986: 76: 1269.
10. 10 Marmont AM, Horowitz MM, Gale RP, et al. T‐cell depletion of HLA‐identical transplants in leukemia. Blood 1991: 78: 2120.
11. 11 Kolb HJ, Schattenberg A, Goldman JM, et al. Graft‐vs‐leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995: 86: 2041.
12. 12 Van Rhee F, Lin F, Cullis JO, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994: 83: 3377.
13. 13 Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukeocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft‐versus‐leukemia responses from graft‐versus‐host disease. Blood 1995: 86: 1261.
14. 14 Cullis JO, Jiang YZ, Schwarer AP, Hughes TP, Barrett AJ, Goldman JM. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 1992: 79: 1379.
15. 15 Antin JH. Graft‐versus‐leukemia: no longer an epiphenomenon. Blood 1993: 82: 2273.
16. 16 Drobyski WR, Keever CA, Roth MS, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T‐cell dose. Blood 1993: 82: 2310.
17. 17 Apperley JF, Jones L, Hale G, et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T‐cell depletion with Campath‐1 reduces the incidence of graft‐versus‐host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1986: 1: 53.
18. 18 Goldman JM, Gale RP, Bortin MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T‐cell depletion. Ann Intern Med 1988: 108: 806.
19. 19 Mackinnon S, Barnett L, Heller G, O'Reilly RJ. Minimal residual disease is more common in patients who have mixed T‐cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood 1994: 83: 3409.
20. 20 Papadopoulos EB, Carabasi MH, Castro‐Malaspina H, et al. T‐cell‐depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft‐versus‐host disease. Blood 1998: 91: 1083.
21. 21 Cardoso AA, Seamon MJ, Afonso HM, et al. Ex vivo generation of human anti‐pre‐B leukemia‐specific autologous cytolytic T cells. Blood 1997: 90: 549.
22. 22 Brenner M & Porcelli S. Antigen presentation: a balanced diet. Science 1997: 277: 332.
23. 23 Offit K, Burns JP, Cunningham I, et al. Cytogenetic analysis of chimerism and leukemia relapse in chronic myelogenous leukemia patients after T cell‐depleted bone marrow transplantation. Blood 1990: 75: 1346.
24. 24 Apperley JF, Rassool F, Parreira A, et al. Philadelphia‐positive metaphases in the marrow after bone marrow transplantation for chronic granulocytic leukemia. Am J Hematol 1986: 22: 19.
25. 25 Radich JP, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the BCR‐ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995: 85: 2632.
26. 26 Hughes TP, Morgan GJ, Martiat P, Goldman JM. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 1991: 77: 874.
27. 27 Pichert G, Alyea EP, Soiffer RJ, Roy D‐C, Ritz J. Persistence of myeloid progenitor cells expressing BCR‐ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Blood 1994: 84: 2109.
28. 28 Delage R, Soiffer RJ, Dear K, Ritz J. Clinical significance of bcr‐abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood 1991: 78: 2759.
29. 29 Lee M, Khouri I, Champlin R, et al. Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation. Br J Haematol 1992: 82: 708.
30. 30 Pichert G & Ritz J. Clinical significance of bcr‐abl gene rearrangement detected by the polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Leuk Lymphoma 1993: 10: 1.
31. 31 Sawyers CL, Timson L, Kawasaki ES, Clark SS, Witte ON, Champlin R. Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. Proc Natl Acad Sci USA 1990: 87: 563.
32. 32 Rapanotti MC, Arcese W, Buffolino S, et al. Sequential molecular monitoring of chimerism in chronic myeloid leukemia patients receiving donor lymphocyte transfusion for relapse after bone marrow transplantation. Bone Marrow Transplant 1997: 19: 703.
33. 33 Champlin R. Graft‐versus‐leukemia without graft‐versus‐host disease: an elusive goal of bone marrow transplantation. Semin Hematol 1992: 29 (Suppl. 2): 46.
34. 34 Champlin RE. Separation of graft‐vs‐host disease and graft‐vs‐leukemia against chronic myelogenous leukemia. Exp Hematol 1995: 23: 1148.
35. 35 Collins Rh Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997: 15: 433.
36. 36 Raanani P, Dazzi F, Sohal J, et al. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol 1997: 99: 945.
37. 37 Bacigalupo A, Soracco M, Vassallo F, et al. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant 1997: 19: 927.
38. 38 Orchard PJ, Miller JS, McGlennen R, Davies SM, Ramsay NKC. Graft‐versus‐leukemia is sufficient to induce remission in juvenile myelomonocytic leukemia. Bone Marrow Transplant 1998: 22: 201.
39. 39 Porter DL, Roth MS, Lee SJ, McGarigle C, Ferrara JLM, Antin JH. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996: 18: 975.
40. 40 Okumura H, Takamatsu H, Yoshida T. Donor leucocyte transfusions for relapse in myelodysplastic syndrome after allogeneic bone marrow transplantation. Br J Haematol 1996: 93: 386.
41. 41 Rondón G, Giralt S, Huh Y, et al. Graft‐versus‐leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1996: 18: 669.
42. 42 Van Besien KW, Lima M, Giralt SA, et al. Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft‐versus‐lymphoma effect. Bone Marrow Transplant 1997: 19: 977.
43. 43 Khouri I, Keating MJ, Przepiorka D, et al. Engraftment and induction of GVL with fludarabine‐based non‐ablative preparative regimen in patients with chronic lymphocytic leukemia. Blood 1996: 88 (Suppl. 1): 301a.
44. 44 Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LLM, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997: 90: 4206.
45. 45 Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft‐versus‐myeloma effect: proof of principle. Blood 1996: 87: 1196.
46. 46 Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ. Graft‐versus‐myeloma effect in two cases. Lancet 1996: 347: 800.
47. 47 Goulmy E, Voogt P, Van Els C, De Bueger M, Van Rood J. The role of minor histocompatibility antigens in GvHD and rejection: a mini‐review. Bone Marrow Transplant 1991: 7 (Suppl. 1): 49.
48. 48 Falkenburg JHF, Goselink HM, Van der Harst D, et al. Growth inhibition of clonogeneic leukemic pre‐cursor cells by minor histocompatibility antigen specific cytotoxic T lymphocytes. J Exp Med 1991: 174: 27.
49. 49 Beatty PG. National heart, lung, and blood institute (NHLBI) workshop on the importance of minor histocompatibility antigens in marrow transplantation. Exp Hematol 1997: 25: 548.
50. 50 De Beuger M, Bakker A, Van Rood JJ, Van Der Woude F, Goulmy E. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity amon human cytotoxic T lymphocyte defined non‐MHC antigens. J Immunol 1992; 149: 1788.
51. 51 Kernan NA & Dupont B. Minor histocompatibility antigens and marrow transplantation. NEJM 1996: 334: 323.
52. 52 Beatty PG. Minor histocompatibility antigens. Exp Hematol 1993: 21: 1514.
53. 53 Perreault C, Décary F, Brochu S, Gyger M, Bélanger R, Roy D. Minor histocompatibility antigens. Blood 1990: 76: 1269.
54. 54 Marijt WAF, Veenhof WFJ, Brand A, et al. Minor histocompatibility antigen‐specific cytotoxic T cell lines, capable of lysing human hematopoietic progenitor cells, can be generated in vitro by stimulation with HLA‐ identical bone marrow cells. J Exp Med 1991: 173: 101.
55. 55 Faber LM, Van der Hoeven J, Goulmy E, et al. Recognition of clonogenic leukemic cells, remission bone marrow and HLA‐identical donor bone marrow by CD8 + or CD4 + minor histocompatibility antigen‐specific cytotoxic T lymphocytes. J Clin Invest 1995: 96: 877.
56. 56 Jiang Y‐Z, Kanfer EJ, Macdonald D, Cullis JO, Goldman JM, Barrett AJ. Graft‐versus‐leukaemia following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes reacting to host leukaemia cells. Bone Marrow Transplant 1991: 8: 253.
57. 57 Sosman JA, Oettel KR, Smith SD, Hank JA, Fisch P, Sondel PM. Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA‐D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells. Blood 1990: 75: 2005.
58. 58 Marijt WAF, Veenhof WFJ, Goulmy E, Willemze R, Van Rood JJ, Falkenburg JHF. Minor histocompatibility antigens HA‐1‐‐2‐, and ‐4‐, and HY‐specific cytotoxic T‐cell clones inhibit human hematopoietic progenitor cell growth by a mechanism that is dependent on direct cell‐cell contact. Blood 1993: 82: 3778.
59. 59 Van der Harst D, Goulmy E, Falkenburg JHF, et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T‐cell clones. Blood 1994: 83: 1060.
60. 60 Ueno NT, Rondón G, Mirza NQ, et al. Allogeneic peripheral‐blood progenitor‐cell transplantation for poor‐risk patients with metastatic breast cancer. J Clin Oncol 1998: 16: 986.
61. 61 Eibl B, Schwaighofer H, Nachbaur D, et al. Evidence for a graft‐versus‐tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996: 88: 1501.
62. 62 Korngold R & Sprent J. T cell subsets and graft‐versus‐host disease. Transplantation 1987: 44: 335.
63. 63 Korngold R & Sprent J. Variable capacity of L3, T4 + T cells to cause lethal graft versus host disease across minor histocompatibility barriers in mice. J Exp Med 1987: 165: 52.
64. 64 Ferrara JLM & Deeg HJ. Mechanisms of disease: graft‐versus‐host disease. N Engl J Med 1991: 324: 667.
65. 65 Sakamoto H, Michaelson J, Jones WK, et al. Lymphocytes with a CD4 + CD8– CD3– phenotype are effectors of experimental cutaneous graft‐versus‐host disease. Proc Natl Acad Sci USA 1991: 88: 10890.
66. 66 Ferrara JLM, Guillen FJ, Vandijken PJ, Marion A, Murphy GF, Burakoff SJ. Evidence that large granular lymphocytes of donor origin mediate acute graft‐versus‐host disease. Transplantation 1989: 47: 50.
67. 67 Ferrara JLM, Abhyankar S, Gilliland DG. Cytokine storm of graft‐versus‐host disease: a critical effector role for interleukin‐1. Transplant Proc 1993: 25: 1216.
68. 68 Faber LM, Van Luxemburg‐Heijs SAP, Willemze R, Falkenburg JHF. Generation of leukemia‐reactive cytotoxic T lymphocyte clones from the HLA‐identical bone marrow donor of a patient with leukemia. J Exp Med 1992: 176: 1283.
69. 69 Truitt RL & Atasoylu AA. Contribution of CD4 + and CD8 + T cells to graft‐versus‐host disease and graft‐versus‐leukemia reactivity after transplantation of MHC‐compatible bone marrow. Bone Marrow Transplant 1991: 8: 51.
70. 70 Okunewick JP, Kociban DL, Machen LL, Buffo MJ. The role of CD4 and CD8 T cells in the graft‐versus‐leukemia response in Rauscher murine leukemia. Bone Marrow Transplant 1991: 8: 445.
71. 71 Okunewick JP, Kociban DL, Machen LL, Buffo MJ. Evidence for a possible role of Asialo‐GM1‐positive cells in the graft‐versus‐leukemia repression of a murine type‐C retroviral leukemia. Bone Marrow Transplant 1995: 16: 451.
72. 72 Jiang Y‐Z & Barrett AJ. Cellular and cytokine mediated effects of CD4‐positive lymphocyte lines generated in vitro against chronic myelogeneous leukemia. Exp Hematol 1995: 23: 1167.
73. 73 Jiang YZ, Mavroudis D, Dermime S, et al. Alloreactive CD4 + T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. Br J Haematol 1996: 93: 606.
74. 74 Jiang YZ, Barrett AJ, Goldman JM, Mavroudis DA. Association of natural killer cell immune recovery with a graft‐versus‐leukemia effect independent of graft‐versus‐host disease following allogeneic bone marrow transplantation. Ann Hematol 1997: 74: 1.
75. 75 Zeis M, Uharek L, Glass B, et al. Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in mice. Transplantation 1995: 59: 1734.
76. 76 Glass B, Uharek L, Zeis M, Loeffler H, Mueller‐Ruchholtz W, Gassmann W. Graft‐versus‐leukaemia activity can be predicted by natural cytotoxicity against leukaemia. Br J Haematol 1996: 93: 412.
77. 77 Hauch M, Gazzola MV, Small T, et al. Anti‐leukemia potential of interleukin‐2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 1990: 75: 2250.
78. 78 Giralt SA & Champlin RE. Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood 1994: 84: 3603.
79. 79 Hoffmann T, Theobald M, Bunjes D, Weiss M, Heimpel H, Heit W. Frequency of bone marrow T cells responding to HLA‐identical non‐leukemic and leukemic stimulator cells. Bone Marrow Transplant 1993: 12: 1.
80. 80 Keil F, Haas OA, Fritsch G, et al. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Blood 1997: 89: 3113.
81. 81 Champlin R, Ho W, Gajewski J, et al. Selective depletion of CD8 + T lymphocytes for prevention of graft‐versus‐host disease after allogeneic bone marrow transplantation. Blood 1990: 76: 418.
82. 82 Champlin RE, Jansen J, Ho W, et al. Retention of graft‐versus‐leukemia using selective depletion of CD8 positive T lymphocytes for prevention of graft versus host disease following bone marrow transplantation for chronic myelogenous leukemia. Transplant Proc 1991: 23: 1695.
83. 83 Nimer SD, Giorgi J, Gajewski JL, et al. Selective depletion of CD8 + cells for prevention of graft‐versus‐host disease after bone marrow transplantation: a randomized controlled trial. Transplantation 1994: 57: 82.
84. 84 Giralt S, Hester J, Huh Y, et al. CD8 + depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: graft vs leukemia without graft vs. host disease. Blood 1995: 86: 4337.
85. 85 Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and efficacy of defined doses of CD4 + donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998: 91: 3671.
86. 86 Bonini C, Ferrari G, Verzeletti S, et al. HSV‐TK gene transfer into donor lymphocytes for control of allogeneic graft‐versus‐leukemia. Science 1997: 276: 1719.
87. 87 Munshi NC, Govindarajan R, Drake R, et al. Thymidine kinase (TK) gene‐transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood 1997: 89: 1334.
88. 88 Tiberghien P, Reynolds CW, Keller J, et al. Ganciclovir treatment of herpes simplex thymidine kinase‐ transduced primary T lymphocytes: an approach for specific in vivo donor T‐cell depletion after bone marrow transplantation. Blood 1994: 84: 1333.
89. 89 Cavazzana‐Calvo M, Stephan JL, Sarnacki S, et al. Attenuation of graft‐versus‐host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H‐2 haplotype disparate mouse combination. Blood 1994: 83: 288.
90. 90 Mavroudis DA, Dermime S, Molldrem J, et al. Specific depletion of alloreactive T cells in HLA‐identical siblings: a method for separating graft‐versus‐host and graft‐versus‐leukaemia reactions. Br J Haematol 1998: 101: 565.
91. 91 Smit WM, Rijnbeek M, Van Bergen CAM, Willemze R, Falkenburg JHF. Generation of leukemia‐reactive cytotoxic T lymphocytes from HLA‐identical donors of patients with chronic myeloid leukemia using modifications of a limiting dilution assay. Bone Marrow Transplant 1998: 21: 553.
92. 92 Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog‐containing chemotherapy: harnessing graft‐versus‐ leukemia without myeloablative therapy. Blood 1997: 89: 4531.
93. 93 Khouri I, Keating M, Korbling M, et al. Transplant Lite: induction of graft‐versus‐leukemia using fludarabine‐based nonablative chemotherpy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998: 16: 2817.
94. 94 Giralt S, Cohen A, Mehra R, et al. Preliminary results of fludarabine/melphalan or 2CDA/melphalan as preparative regimens for allogeneic progenitor cell transplantation in poor candidates for conventional myeloablative conditioning. Blood 1997; 90: 1853.
95. 95 Slavin S, Nagler A, Naparstek E, et al. Non‐myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998: 91: 756.
96. 96 Kelemen E, Masszi T, Reményi P, Barta A, Pálóczi K. Reduction in the frequency of transplant‐related complications in patients with chronic myeloid leukemia undergoing BMT preconditioned with a new, non‐myeloablative drug combination. Bone Marrow Transplant 1998: 21: 747.
97. 97 Bacigalupo A, Van Lint MT, Occhini D, et al. Increased risk of leukemia relapse with high‐dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991: 77: 1423.